Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - PA: Cancer Research (bridge funding)

Université de Montréal

$100,000.00

Antiestrogen-HDACi hybrid molecules for breast cancer treatment.

FY 2011-12

Summary
Breast cancer is the most common form of cancer in women in the Western world. As growth of 2/3 of breast tumors can be stimulated by the hormone estrogen, compounds that block its action (antiestrogens, AEs) have been used in the clinic with considerable success. However, a comprehensive study showed that mortality rates in women with early stage breast cancers after 5 years of treatment is still 25%. Lab studies including our own have shown that therapy may be improved by combining AEs with another class of drugs called histone deacetylase inhibitors (HDACi's). In addition, we have previously shown that activity of AE and HDACi drugs could be combined in a single molecule, with potential advantages in facilitating delivery and association with additional anti-cancer drugs. Our goals here are to fully investigate combination therapies of AEs and HDACi's and to create optimal hybrid molecules and to test their anti-tumor activities in experimental models of breast cancer.
Program
Operating Grant - PA: Cancer Research (bridge funding)
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
260641
Name
Mader Sylvie N
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Antiestrogen-HDACi hybrid molecules for breast cancer treatment.
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Cancer Research (bridge funding)
Keyworddelim
Antiestrogens; Breast Cancer; Cell Culture; Drug Combinations; Estrogen Receptor; Histone Deacetylase Inhibitors; Hybrid Drugs; Pharmacokinetics; Structure Activity Relationship; Xenograft Models
Abstract
Breast cancer is the most common form of cancer in women in the Western world. As growth of 2/3 of breast tumors can be stimulated by the hormone estrogen, compounds that block its action (antiestrogens, AEs) have been used in the clinic with considerable success. However, a comprehensive study showed that mortality rates in women with early stage breast cancers after 5 years of treatment is still 25%. Lab studies including our own have shown that therapy may be improved by combining AEs with another class of drugs called histone deacetylase inhibitors (HDACi's). In addition, we have previously shown that activity of AE and HDACi drugs could be combined in a single molecule, with potential advantages in facilitating delivery and association with additional anti-cancer drugs. Our goals here are to fully investigate combination therapies of AEs and HDACi's and to create optimal hybrid molecules and to test their anti-tumor activities in experimental models of breast cancer.
Competitiondate
201203
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mader, Sylvie N; Gleason, James L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
Université de Montréal - $100,000 Grant (2011-12) | Canada Spends